In Phase III clinical trials, the new cancer drug was tested against standard treatments. The trials measured outcomes such as progression-free survival and overall survival. Results indicated that patients receiving the new drug had significantly longer progression-free survival rates compared to those on traditional treatments. Furthermore, improvements in overall survival were also observed, although these varied depending on cancer type and stage.
